Eli Lilly's Trial Halt: Buying Opportunity?

Eli Lilly's stock stumbled after abruptly halting a key muscle-loss prevention trial for its blockbuster obesity drug, Zepbound, spooking investors despite another similar trial moving forward. Is this a short-term dip or a sign of deeper issues for the pharmaceutical giant, whose stock has otherwise seen explosive growth? Find out if this could be a buying opportunity. Hosted on Acast. See acast.com/privacy for more information.